Kindeva Careers
Inventive, curious, and committed to results? We’re hiring.
Explore Job OpportunitiesWe’re dedicated to decarbonizing the global inhaler market and committed to leading the transition to the next generation of green propellants. Our low-GWP formulations will be easier on the environment while delivering performance patients can trust.
˅
The Reality
pMDIs are responsible for 3% of global emissions in the UK.* At Kindeva, we’re on a mission to change that. Our passion for innovation is matched by a track record of leadership in sustainability.
Additional Resources:
Six Inhaler Sustainability Myths – And Why They Must Be Busted
by Louise Righton, Global Strategic Marketing Leader, Inhaled Drug Delivery
A study authored by Frontier Economics and provided during the PCRS Respiratory Conference 2021. For additional details, click here.
* NHS England and NHS Improvement, Delivering a ‘Net Zero’ National Health Service (London: Skipton House, 2020)
˅
Current Efforts
- By 2022, Kindeva will install two new manufacturing lines capable of filling inhalers with HFA-152a and/or HFO-1234ze–propellants that have 90% and 99.9% lower Global Warming Potential (GWP) than P134a, the greenest propellant currently used. Click here to read more on initial efforts.
- By 2025, we will strive to introduce the first products using these propellants to the market, subject to regulatory approvals.
˅
Our Vision
We will lead the industry’s transition to greener gasses just as we led the transition from CFC- to HFA-based inhalers in the 1990s, developing the world’s first CFC-free pMDI and the world’s first CFC-free nasal pMDI.
Learn more about sustainability and our efforts at Kindeva:
Kindeva Drug Delivery commits to sustainable inhaler production with significant new manufacturing investment
Accelerating sustainable healthcare product development
Kindeva Drug Delivery Announces Knowledge Transfer Partnership with Loughborough University to Study Sustainable Propellants